Wednesday, October 3, 2012

Mylan Sues USFDA and urges to forfeit Ranbaxy Exclusivity on Diovan

In a lawsuit filed by Mylan, it has claimed that he USFDA should forfeit Ranbaxy exclusivity on Diovan. According to Mylan, Ranbaxy has failed to receive the tentative approval within the statutory 30 months litigation stay and USFDA should forfeit its 180 days exclusivity.
Diovan generates approximately  $950 million in annual sales in the US from Diovan (excluding Diovan HCT).